ALLO - Allogene Therapeutics Inc

2.3
0.020   0.870%

Share volume: 10,026,466
Last Updated: 05-12-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$2.28
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.88%
1 Month
-24.84%
3 Months
27.78%
6 Months
91.67%
1 Year
103.54%
2 Year
-20.69%
Key data
Stock price
$2.30
P/E Ratio 
N/A
DAY RANGE
$2.27 - $2.39
EPS 
-$0.87
52 WEEK RANGE
$0.94 - $4.46
52 WEEK CHANGE
$141.39
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
243.778 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,483,112
AVERAGE 30 VOLUME 
$16,552,477
Company detail
CEO: David D. Chang
Region: US
Website: allogene.com
Employees: 310
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Recent news